Propiomazine

Summary

Propiomazine (CHEMBL1201210) is an approved small-molecule phenothiazine antipsychotic drug (ATC N05CM06).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CM06
• Chemistry: 340.5 Da · C20H24N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201210
Name	Propiomazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4940
ChEBI	CHEBI:8491
ATC	N05CM06
Molecular formula	C20H24N2OS
Molecular weight	340.5
InChIKey	UVOIBTBFPOZKGP-UHFFFAOYSA-N

SMILES: CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C

IUPAC name: 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one

ChEBI definition: A member of the class of phenothiazines that is 10H-phenothiazine substituted by a 2-(dimethylamino)propyl group at nitrogen atom and a propanoyl group at position 2.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, dopaminergic antagonist, serotonergic antagonist, muscarinic antagonist, histamine antagonist, sedative.

Also known as: CB 1678, CB-1678, Dorevan, Dorevane, Indorm, Propiomazina, Propiomazine, Propavan, WY-1359, PROPIOMAZINE, propiomazine

Parent form; salt/anhydrous children: CHEMBL1201068

Patent coverage: 343 distinct patent families (1,120 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,113 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 16 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor.

Bioactivity

ChEMBL activities: 17 potent at pChembl ≥ 5 of 18 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR2A	7.63	AC50	23.3	nM	CHEMBL_ACT_25173472
ADRA1A	7.53	AC50	29.4	nM	CHEMBL_ACT_25137688
HRH1	7.47	AC50	34	nM	CHEMBL_ACT_25212095
CHRM1	6.92	AC50	120	nM	CHEMBL_ACT_25135034
HTR2C	6.75	AC50	180	nM	CHEMBL_ACT_25131405
CHRM3	6.75	AC50	180	nM	CHEMBL_ACT_25136296
HTR2B	6.64	AC50	230	nM	CHEMBL_ACT_25227139
CHRM2	6.58	AC50	265.5	nM	CHEMBL_ACT_25195163
ADRA2B	6.5	AC50	320	nM	CHEMBL_ACT_25143298
DRD3	6.28	AC50	530	nM	CHEMBL_ACT_25193123
KCNH2	6.16	AC50	685	nM	CHEMBL_ACT_25117253
HTR2A	6	AC50	1000	nM	CHEMBL_ACT_25224796
CHRM2	5.96	AC50	1100	nM	CHEMBL_ACT_25213348
OPRK1	5.77	AC50	1700	nM	CHEMBL_ACT_25129059
DRD2	5.58	AC50	2600	nM	CHEMBL_ACT_25139919
HTR1A	5.57	AC50	2700	nM	CHEMBL_ACT_25215719
ADRA2C	5.35	AC50	4500	nM	CHEMBL_ACT_25147461

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).